Role of PET in lymphoma (Q38195220)

30 August 2017

1 reference

title

Role of PET in lymphoma (English)

1 reference

30 August 2017

Andrea Gallamini

1 reference

30 August 2017

Anna Borra

series ordinal

1 reference

30 August 2017

publication date

1 June 2014

1 reference

Current Treatment Options in Oncology

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

248-261

1 reference

Over-expression of facilitative glucose transporter genes in human cancer

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Increases in mRNA levels of glucose transporters types 1 and 3 in Ehrlich ascites tumor cells during tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

FDG accumulation and tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Utility of FDG-PET scanning in lymphoma by WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organiza

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Imaging in staging of malignant lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Redirecting traffic using the XPO1 police.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Report on the First International Workshop on Interim-PET-Scan in Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Hodgkin lymphoma: Response assessment by revised International Workshop Criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Role of positron emission tomography in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Salvage therapy for Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Is there a place for routine imaging for patients in complete remission from aggressive lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-014-0278-4

Role of functional imaging in the management of lymphoma

21 January 2018

1 reference

12 December 2020

Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia

1 reference

12 December 2020

Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study

1 reference

12 December 2020

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

1 reference

12 December 2020

Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.

1 reference

12 December 2020

PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

1 reference

12 December 2020

Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography

1 reference

12 December 2020

Staging DLBCL: bone marrow biopsy or PET-CT?

1 reference

12 December 2020

The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease

1 reference

12 December 2020

Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake.

1 reference

12 December 2020

Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important?

1 reference

12 December 2020

Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake.

1 reference

12 December 2020

18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

1 reference

12 December 2020

Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission

1 reference

12 December 2020

Residual mass in lymphoma may not be residual disease

1 reference

12 December 2020

Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management

1 reference

12 December 2020

Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma

1 reference

12 December 2020

Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes

1 reference

12 December 2020

10.1007/S11864-014-0278-4

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1032330621

0 references

1 reference